Newly approved head and neck cancer treatment improves care for first time in more than 20 years

There’s encouraging news from the UK about a newly approved treatment approach for people with locally advanced head and neck cancer.

An immunotherapy medicine called pembrolizumab (Keytruda) has been recommended for use before surgery and after surgery alongside radiotherapy (with or without chemotherapy). This is significant because it’s the first treatment in more than 20 years to show improved outcomes compared with the previous standard approach.

Pembrolizumab works by helping the body’s immune system recognise and attack cancer cells, rather than targeting the cancer directly like chemotherapy does.

Research behind this decision showed that adding pembrolizumab to treatment helped some patients stay cancer-free for longer after treatment than with standard care alone.

While this approval currently applies to patients in England, it’s an important step forward internationally and shows how immunotherapy is moving earlier into treatment pathways, not just being used when cancer returns or spreads.

Why this matters for our community

• It represents real progress after many years with limited change in treatment options

• It shows immunotherapy is becoming part of treatment earlier

• It offers hope for better long-term outcomes and potentially fewer severe long-term side effects for some people

Research like this helps shape future treatment here in Aotearoa New Zealand too.

Read more here. https://pharmaceutical-journal.com/article/news/newly-approved-head-and-neck-cancer-treatment-improves-care-for-first-time-in-more-than-20-years